An article was posted today with results of a CRC

Quote:

---

The antibody-drug conjugate trastuzumab deruxtecan (T-DXd, Enhertu) proved active in a phase II study of advanced HER2-positive colorectal cancer (CRC).

Almost 40% of patients treated with the recommended dose had objective responses and almost half had stable disease. The patients had a median progression-free survival (PFS) of 5.8 months and overall survival (OS) of 13.4 months. The agent had activity in cancers with and without RAS mutations.

"Given scarce data on HER2-targeting treatments in patients with HER2-positive metastatic colorectal cancer, trastuzumab deruxtecan offers a promising option to meet a substantial clinical need," the authors stated. "Although HER2 amplification and RAS wild-type status are required for patients to benefit from dual HER2-directed therapy [with trastuzumab and pertuzumab [Perjeta]), results from [this study and an earlier one] suggest that patients with HER2 immunochemistry score 3+ might derive greater clinical benefit from trastuzumab deruxtecan than patients with lower levels of HER2 expression ... including patients with RAS mutations and previous dual HER2 therapy."

---